The historical rank and industry rank for Everest Medicines's Gross Margin % or its related term are showing as below:
HKSE:01952'
s Gross Margin % Range Over the Past 10 Years
Min: 57.58 Med: 63.69 Max: 72.67
Current: 72.67
During the past 6 years, the highestGross Margin % of Everest Medicines was 72.67%. The lowest was 57.58%. And the median was 63.69%.
HKSE:01952's Gross Margin % is ranked better than 65.19% of 747
companies
in the Biotechnology industry
Industry Median: 60.43
vs HKSE:01952: 72.67
Everest Medicines had a gross margin of 73.43% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Everest Medicines was 0.00% per year.
Everest Medicines Gross Margin % Historical Data
The historical data trend for Everest Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Everest Medicines's Gross Margin %
For the Biotechnology subindustry, Everest Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Everest Medicines had a gross margin of 73.43% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Everest Medicines Gross Margin % Related Terms
Thank you for viewing the detailed overview of Everest Medicines's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Everest Medicines (HKSE:01952) Business Description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01952 has been successfully added to your 